We describe a new model of myeloma bone disease in which b 2 m NOD/SCID mice injected with KMS-12-BM cells develop medullary disease after tail vein administration. Micro-computed tomography analysis demonstrated significant bone loss in the tibiae and vertebrae of diseased animals compared to controls, with loss of cortical bone (Po0.01), as well as trabecular bone volume, thickness and number (Po0.05 for all). Bone marrow of diseased animals demonstrated an increase in osteoclasts (Po0.01) and reduction in osteoblasts (Po0.01) compared to control animals. Both bone loss and osteoclast increase correlated with the degree of disease involvement. Mesenchymal stem cells (MSCs) were lentivirally transduced to express human osteoprotegerin (hOPG). Systemic administration of OPG expressing MSC reduced osteoclast activation (Po0.01) and trabecular bone loss in the vertebrae (Po0.05) and tibiae of diseased animals, to levels comparable to non-diseased controls. Because of its predominantly medullary involvement and quantifiable parameters of bone disease, the KMS-12-BM xenogeneic model provides unique opportunities to test therapies targeted at the bone marrow microenvironment.
Introduction
Multiple myeloma (MM) is a B-cell neoplasm characterized by the clonal expansion of plasma cells in the bone marrow. Bone destruction, which is present in over 80% of patients, 1 is responsible for the most debilitating clinical features of this disease. Although the mechanisms that lead to the development of myeloma bone disease are not fully understood, histomorphometric studies have shown uncoupling of the normal process of bone remodelling. Bone resorption is enhanced due to increased numbers of osteoclasts, whereas bone formation is reduced. 2, 3 Increased osteoclast activity is generated through interactions between osteoclast precursors, stromal/osteoblastic cells and the malignant plasma cells. These cellular interactions lead to the production of osteoclast-activating factors (OAFs) of which the major ones are the receptor of nuclear factor-kB ligand (RANKL) and macrophage inflammatory protein 1-a (MIP-1a). RANKL has been shown to play a crucial role in osteoclast development. 4 RANKL is expressed by stromal cells and osteoblasts in the local bone marrow microenvironment, and binds to RANK on the surface of osteoclast precursors to stimulate osteoclast differentiation and activation. 5 Osteoprotegerin (OPG) is a naturally occurring soluble decoy receptor for RANKL, inhibiting its interaction with RANK and preventing osteoclast formation. 6 Evidence suggests that the increase in osteoclast activity in myeloma is due to an imbalance in the ratio of RANKL to OPG. RANKL expression is increased in bone marrow stroma cells, 7, 8 and OPG is reduced in the bone marrow 8 and serum 9 of patients with myeloma. MIP-1a is an OAF produced directly by MM cells that induces osteoclast formation in human bone marrow cultures and its expression is elevated in the bone marrow of MM patients compared to healthy controls. 10 In addition to the increase in osteoclast activity, bone loss is exacerbated by suppression of osteoblastic activity. Biological mechanisms involved in osteoblast inhibition by MM cells include modulation of Runx2/Cbfa1, 11 inhibition of Wnt signalling 12 and cytokines such as interleukin-3 (IL-3) and IL-7. 13 The pathways that lead to increased osteoclast activity and osteoblast suppression present attractive therapeutic targets. RANKL blockade, achieved with recombinant OPG 14 or RANKFc 7 in murine models of osteolytic bone disease inhibited osteoclastogenesis and prevented bone loss. Similarly, an antisense construct targeting MIP-1a reduced bone loss in a xenogeneic model of osteolytic bone disease. 15 These results provide compelling evidence for the involvement of these pathways in vivo. The successful development of such therapies targeting mechanisms of bone disease requires reproducible and accessible in vivo models of medullary myeloma, which are currently lacking. Syngeneic models, such as the 5T2 murine model, are useful models of medullary MM, but are not widely available. Xenogeneic models employing human myeloma cell lines cultured in vitro and injected systemically into immunodeficient mice frequently develop extramedullary disease, [16] [17] [18] [19] which makes assessment of therapies targeted to the bone marrow microenvironment difficult. The SCID/Hu model, 20 where human fetal bones (or rabbit bones in the SCID-Rab model 21 ) provide the bone marrow microenvironment for primary myeloma cells, is clearly useful but does not reflect the widespread anatomical nature of this disease or lend itself to investigations of tumour cell homing or migration.
With these issues in mind we aimed to set up and characterize a new model of medullary MM with associated bone disease, using immunohistochemistry, histomorphometry and microcomputed tomography (micro-CT). We have used this model to test the efficacy of gene-modified human mesenchymal stem cells (hMSCs) overexpressing OPG. We have shown that enforced expression of OPG in this xenogeneic model reverses osteoclast activation and trabecular bone loss.
Materials and methods

Cell lines
KMS-12-BM was provided by Dr T Otsuki (Kawasaki Medical School, Okoyama, Japan). All other cell lines were purchased from (ATCC, Teddington, Middlesex, UK). KMS-12-BM were maintained in culture in RPMI 1640 supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin, and 100 mg/ml streptomycin. HeLa and 293 T-cell lines were maintained in culture in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS, 100 U ml penicillin, and 100 mg/ml streptomycin.
Xenogeneic myeloma model
All procedures involving the use and care of animals were performed in accordance with the Animals Scientific Procedures Act (1986), were approved by the Institutional Animal Care Use and licensed by the Home Office. All experiments involved unconditioned 6-to 8-week-old b 2 m NOD/SCID mice, housed under positive pressure in individually ventilated cages (Tecniplast, Northamptonshire, UK).
Subcutaneous tumours were established after injection of 1 Â 10 7 KMS-12-BM, and tumour measurements performed in two dimensions with callipers at serial time points. In subsequent experiments mice received either tumour (1 Â 10 6 or 1 Â 10 7 KMS-12-BM cells), or vehicle control (phosphatebuffered saline) by tail vein injection. Animals were killed when they developed hind limb paralysis or behavioural changes necessitating killing. To assess the effect of gene-modified MSC in this tumour model, 1 Â 10 6 MSC OPG , MSC GPO , unmodified MSC or vehicle control, were injected by tail vein 2, 3 and 4 weeks after administration of 1 Â 10 7 KMS-12-BM. These mice were killed at 6 weeks and the tibiae and lumbar vertebrae were obtained for analysis.
Histological and histochemical analysis
Tibiae, lumbar vertebrae and visceral organs were fixed in formalin. Tibiae and lumbar vertebrae were decalcified in EDTA and embedded in paraffin, and 3 mm sections were cut and stained with haematoxylin and eosin. Immunohistochemistry to detect KMS-12-BM in vivo was performed using VS38C (Dako, Ely, Cambridgeshire, UK) on paraffin-embedded sections. VS38C is a mouse anti-human monoclonal antibody that detects a transcription factor produced by normal and malignant plasma cells. 22 Briefly, following blockade of endogenous peroxidase, VS38C primary antibody was applied (1 in 100 dilution), followed by secondary antibody visualized with HRP/DAB system (Dako, UK). Tumour infiltration in the marrow space of the tibiae and vertebrae was graded as the proportion of positively stained cells to total number of cells as follows; greater than 70% involved ( þ þ þ ), between 30 and 69% involved ( þ þ ), and less than 30% ( þ ) or not involved (À). Trabecular bone area (Tb.Ar) as a proportion of the total area was determined in the tibia and lumbar vertebrae, in an area of 0.525 mm 2 and 0.2 mm from the growth plate, using an Osteomeasure analysis system (OsteoMetrics, Decatur, GA, USA). Sections were also stained for the presence of tartrateresistant acid phosphatase (TRAP) to identify osteoclasts and counterstained with Gill haematoxylin. Because bone marrow infiltration by KMS-12-BM resulted in loss of trabecular bone, only osteoclasts lining the endocortical bone surfaces were assessed. Endocortical surfaces were analysed for osteoclastic surface (mm) over total endocortical bone surface (mm) and expressed as a percentage, for 3 mm (tibia) or 2 mm (vertebrae) of endocortical surface beginning 0.2 mm from the growth plate. Osteoblasts were identified as cuboidal cells lining the endocortical surface in sections of tibiae stained with haematoxylin and eosin, and analysed as for osteoclasts (see above).
Micro-CT
Tibiae and lumbar vertebrae were fixed in formalin, and analysed at a pixel size of 4.3 mm using the Skyscan model 1172 and associated analysis software (Skyscan, Aartselaar, Belgium). During scanning, the samples were enclosed in a tightly fitting rigid plastic tube to prevent movement. X-ray source was set to 50 kV, 100 mA with a 0.5 aluminium filter and the sample rotated through 1801 using a 0.71 rotation step. Regions of interest were defined as trabecular or cortical bone that were 0.2 mm from the growth plate and extending a further 1 mm. Thresholding was then applied to the images to segment the bone from the background, and the same threshold setting was used for all samples. The following three-dimensional (3D) parameters were measured: volume, surface and surface-tovolume ratio. To calculate these, the software builds a 3D cuboidal voxel model of bone. The following architectural measurements were then made: trabecular thickness, number and separation.
Isolation and characterization of human mesenchymal stem cells Non-adherent cells were removed after 48 h and adherent cells cultured until they reached confluence. Cells were trypsinized, and subcultured at densities of 1 Â 10 4 /cm 2 . Adipocytic differentiation of MSC was induced by culture in DMEM supplemented by 10% FCS, 1 mM dexamethasone, 10 mg/ml insulin, 100 nM indomethacin and 0.5 mM isobutylmethylxanthine (all from Sigma-Aldrich, Gillingham, Dorset, UK) for 7-10 days, after which adipocyte differentiation was confirmed using direct staining of lipid formation with Nile Red. Osteogenic differentiation of MSC was induced by culture in DMEM supplemented by 10% FCS, dexamethasone, b-glycerophosphate and ascorbic acid (all from Sigma-Aldrich, UK) for 14-21 days. Osteogenic differentiation was confirmed by staining for alkaline phosphatase.
Production of SIN Lentiviral vectors
cDNA for human OPG (hOPG) was originally isolated from MG63 cells, and its sequence corresponds to NM002546 (National Center for Biotechnology Information; C Buckle, unpublished). The cDNA for hOPG was cloned into the pCL10.1 vector in either a forward (producing OPG) or reverse (control) direction upstream of the gene for enhanced green fluorescent protein (eGFP), both under the direction of the murine stem cell virus promoter. Third generation self-inactivating lentivirus were produced as described previously. 23 Briefly, 293 T cells were transfected with four plasmids containing (1) the lentiviral gag-pol genes, (2) the vesicular stomatitis virus glycoprotein envelope gene, (3) the reverse transcriptase, and (4) a bicistronic vector (pCL10.1) as described. Biological titres of the supernatant were determined by limiting dilution on HeLa cells.
Lentiviral transduction of MSC
MSCs at passages 2-4 were plated at a density of 5 Â 10 4 cells per well in a six-well plate. For each of the following 5 days, cells were exposed to viral supernatant at a multiplicity of infection of 2 for 6 h in the presence of polybrene (8 mg/ml), generating MSC OPG (cloned in forward direction, expressing hOPG) or MSC GPO (control). Transduced MSCs were expanded and used for in vivo experiments. Transduction efficiency was determined using fluorescence-activated cell sorting (FACS) analysis for GFP expression. To detect hOPG expression in vitro, conditioned media from MSC cultured in X-VIVO-10 for 72 h was tested in an OPG enzyme-linked immunosorbent assay (ELISA; R&D Systems, Abingdon, Oxfordshire, UK), according to the manufacturer's protocol. In vivo expression of hOPG was determined using a similar ELISA on mouse serum collected at various times after tail vein injection of MSC OPG or MSC GPO (3 Â 10 6 /animal) or vehicle control.
Analysis of short-term homing of MSC in vivo
Short-term homing experiments using PKH26 (PKH)-labelled cells have previously been described. 24 Briefly, MSCs were labelled with 8 mM PKH-26, injected at 2 Â 10 6 per animal by tail vein administration, and murine tissues analysed 24 h later for the presence of PKH-24-positive cells by FACS analysis of single-cell suspensions. At least 100 000 events were collected on the Epics-Elite flow cytometer (Beckman-Coulter, High Wycombe, UK).
Statistical analysis
Comparison between groups was performed by the MannWhitney U test.
Results
Engraftment of KMS-12-BM in b2m NOD/SCID mice
The MM cell line KMS-12-BM was originally isolated from the bone marrow of a patient with non-secretory MM. 25 It is associated with specific cytogenetic abnormalities t(11:14)(q13:q32), which were confirmed (data not shown). To investigate the in vivo tumorigenicity of KMS-12-BM cells and to optimize the immunohistochemical detection of these cells in vivo, 1 Â 10 7 cells in culture were injected subcutaneously into the flank of unconditioned b 2 m NOD/SCID mice. Animals developed palpable solid tumours after 2 weeks. Immunohistochemistry performed on these solid tumours revealed that they expressed CD38, CD138, Pax-5, Mum-1 and VS38C, but not kappa, lambda or CD20 (data not shown). We subsequently used VS38C immunohistochemistry to assess tumour infiltration in diseased animals.
To set up and characterize the xenogeneic myeloma model using KMS-12-BM, 1 Â 10 6 or 1 Â 10 7 cells were injected by tail vein into unconditioned b 2 m NOD/SCID mice. Animals were killed between 5 and 12 weeks, with the onset of hind limb paralysis and behavioural changes such as reduced spontaneous activity and changes in grooming. More rapid tumour take and shorter survival was observed in those mice treated with a higher cell dose ( Figure 1A) . A cell dose of 1 Â 10 7 KMS-12-BM was used in subsequent experiments. Immunohistochemistry with VS38C in diseased animals demonstrated tumour in the bone marrow of the long bones ( Figure 1C ) and vertebrae (data not shown), although the extent of infiltration varied between animals ( Table 1) . FACS analysis of bone marrow mononuclear cells collected from diseased animals demonstrated the presence of CD138-positive cells ( Figure 1B ). Importantly extramedullary disease was unusual, with liver being the only other site of tumour infiltration (small foci of disease in two of five animals), and no disease seen in any other organs, including the spleen and kidney ( Figure 1C ). Occasional tumour cells are seen in the lung, which reflects cells being trapped in the pulmonary vasculature, as there was no evidence of tumour formation ( Figure 1C ).
To determine the kinetics of disease take, a series of animals were killed at different time points following tail vein administration of 1 Â 10 7 KMS-12-BM. A small focus of tumour was first apparent in the tibiae after 3 weeks (data not shown), with increasing bone marrow involvement thereafter, and almost complete effacement of the tibial bone marrow at 6 weeks. This time course of disease development was consistent between experiments.
Cortical and trabecular bone is lost in the KMS-12-BM xenogeneic MM model
Micro-CT has allowed detailed assessment of bone disease in malignant and non-malignant animal models of bone disease. We used this technique to examine bone loss in the tibiae and vertebrae 6 weeks after injection of 1 Â 10 7 KMS-12-BM in comparison with non-diseased controls. Cortical bone was reduced in the tibiae of diseased animals (median cortical thickness 69.9 mm, range 65.8-78.6 vs control median 84.5 mm, range 75.9-90.6, Po0.01) with evidence of lytic lesions (Figure 2a ). Trabecular bone volume (TBV) was similarly reduced in the tibiae of diseased animals (median %TBV 2.9, range 0.9-5.0, vs control median 6.4, range 3.5-10.8, Po0.05), as were trabecular thickness and number (Table 2 ). To confirm that bone loss is caused by tumour infiltration, and because tumour take is variable, we analysed separately those animals with high (470%) and low (o70%) tumour infiltration based on VS38C immunohistochemistry. Loss of trabecular bone is related to the amount of tumour infiltration, with the most striking loss seen in animals with heavy disease burden (Figure 2b ). This suggests that the presence of tumour cells is directly related to bone loss. Interestingly, animals with intermediate disease burden also showed loss of trabecular bone.
Micro-CT analysis demonstrated extensive bone loss in the lumbar vertebrae. Trabecular bone volume was significantly reduced in the vertebrae of diseased animals (median %TBV 9.8, range 8.1-11.8, vs control median 13.1, range 11.1-14.1, Po0.01). In addition, the vertebrae of diseased animals demonstrate significant reduction of trabecular thickness and number ( Table 3) . As seen in the tibiae, the magnitude of bone loss varied directly with the degree of tumour infiltration (Figure 2c ).
To further investigate bone loss in this model, histomorphometric analysis was performed. The tibiae of diseased animals demonstrated a reduction in trabecular bone area (Tb.Ar) (median %Tb.Ar 2.4, range 0.4-6.1 vs control median 4.6, range 1.5-8.9, Po0.05), with representative animals shown in Figure 2d . In keeping with micro-CT analysis, we found that the reduction in trabecular bone was most marked in tibiae with high tumour burden (470%) as revealed by VS38C immuno-histochemistry (median %Tb.Ar 0.7, range 0.1-1.1, Po0.01 compared to control), whereas tibiae without significant tumour involvement had similar Tb.Ar to controls (median 5.1, range 2.7-6.1, Figure 2e ). There was no significant loss of trabecular bone area in the lumbar vertebrae of diseased animals by histomorphometry (%Tb.Ar 10.3, range 7.3-12.5; vs 11.1, range 7.3-15.3 in control mice, NS, Figure 2f ), in contrast to the micro-CT results.
Bone disease in the KMS-12-BM xenogeneic MM model is mediated by an increase in osteoclast numbers and reduced osteoblasts Bone disease in MM is considered to be due to an uncoupling of the normal process of bone remodelling, with an increase in osteoclasts and reduction in osteoblast numbers. To investigate the cellular basis for bone loss in our model, we quantified osteoclast and osteoblast numbers in diseased animals and in non-diseased controls.
Diseased animals demonstrated a marked increase in osteoclasts in the lumbar vertebrae (median %OcPm 8.1, range 3.1-15.9; vs control median 0.9, range 0.2-1.8, Po0.01, Figure 3a ). This increase in osteoclasts was also apparent in the tibiae (diseased animals median %OcPm 6.9, range 2.2-20.1; control median 0.6, range 0.0-2.1, Po0.05, Figure 3a ). In keeping with trabecular bone loss, the increase in osteoclast perimeter was most marked in bones with heavy (470%) tumour infiltration (Figure 3b ). There was a concomitant reduction in osteoblast numbers in diseased animals (median %ObPm 32.5, range 8.8-64.4; vs control median 77.8, range Figure 3c ). Once again the most striking loss of osteoblasts was seen in animals with significant tumour burden (Figure 3d ). These observations suggest that the imbalanced increase in osteoclasts and reduction in osteoblasts is directly related to the extent of tumour infiltration.
Lentiviral transduction of hMSC
Next, we investigated whether this model could be used to test novel therapies that target myeloma bone disease. Human bone marrow-derived MSCs were isolated by standard means and characterized by the ability to differentiate into osteoblasts and adipocytes, and the retention of a stable immunophenotype (SH2 þ , SH4 þ , CD13 þ , CD49e þ , CD34À, CD45À) for up to 14 passages. Using conditions we have previously optimized, 26 early passage 2-4 hMSCs were transduced with a bicistronic lentiviral construct containing cDNA encoding OPG and eGFP (MSC OPG , Figure 4a ). Control MSCs were derived from the same bone marrow donor, and transduced with a bicistronic lentiviral construct with the cDNA for OPG cloned in reverse (MSC GPO , Figure 4a ). Efficient transduction was demonstrated by high GFP expression in transduced MSC (480%). Stable transgene expression was confirmed by detection of OPG in culture supernatants of MSC OPG for up to 16 passages, as well as eGFP expression by flow cytometry. There was no difference in OPG expression detected in vitro between early and late passage gene-modified MSC (Figure 4b ). MSC GPO expressed low levels of hOPG in culture at similar levels to untransduced MSC (data not shown). MSC transduced with lentiviral constructs retain their differentiating capacity and phenotype as reported previously, 26 with no significant differences seen between MSC OPG , MSC GPO and untransduced MSC (data not shown).
In vivo behaviour of gene-modified hMSC
To determine transgene expression in vivo, 3 Â 10 6 MSC OPG or MSC GPO were injected by tail vein into unconditioned b 2 m NOD/SCID mice. hOPG was detected in mouse serum collected 2 weeks after injection in the MSC OPG -treated group only (median 2 ng/ml, range 1.6-2.4) and levels persisted for up to 4 weeks post-administration of gene-modified hMSC. hOPG was consistently undetectable in mice injected with MSC GPO Figures  4c and d) , whereas homing to spleen and lungs was similar between diseased and control animals (data not shown).
Gene-modified MSCs expressing OPG reverse osteoclast activation and reduce bone loss in the KMS-12-BM xenogeneic model
To determine the effect of enforced OPG expression on osteoclast activation and bone loss in this model, 1 Â 10 6 MSC OPG , MSC GPO or unmodified MSCs were injected by tail vein into b 2 m NOD/SCID mice 2, 3 and 4 weeks after administration of 1 Â 10 7 KMS-12-BM (MM cells). Another group of mice were injected with 1 Â 10 7 KMS-12-BM (that is, tumour alone) or vehicle control by tail vein injection. All mice were culled at 6 weeks. There was no significant difference in tumour take between those groups that did and did not receive MSC.
As demonstrated previously mice injected with MM cells alone showed an increase in osteoclasts in the lumbar vertebrae (median %OcPm 8.4, range 3.2-9.5; control median 2.0, range A new xenograft model of myeloma bone disease N Rabin et al 2.0-2.7, Po0.01, Figure 5a ). The administration of MSC GPO or unmodified MSC (control MSC) had no effect on osteoclast numbers in diseased animals (median %OcPm 6.2, range 1.6-10.4, NS, Figure 5a) , when compared to animals that had received MM cells but no MSC. In contrast osteoclast numbers in the group of diseased animals that received MSC OPG were similar to those in non-diseased animals (median %OcPm 2.7, range 0.2-5.5) and significantly lower when compared with the control groups of diseased animals (Po0.01, Figure 5a ). There was a similar effect on osteoclast numbers in the tibiae where the administration of MSC OPG reduced osteoclast numbers (median 3.2, range 0.0-6.7), when compared with the other diseased animals (median 5.0, range 0.3-11.0) although these levels remained higher than those in non-diseased controls (Figure 5b) .
Next, we investigated whether reducing osteoclast numbers using this strategy was able to prevent bone loss in diseased animals. As expected animals that received MM cells alone or in combination with control MSC demonstrated loss of TBV in the vertebrae (median %TBV 8.7, range 7.2-10.4 and 9.5, range 7.3-11.1, respectively) when compared to control non-diseased animals (median 11.1, range 9.7-12.9, Po0.01 and Po0.05, respectively, Figure 5c ). Administration of control MSC had no effect on TBV in diseased animals. In contrast animals that received MSC OPG had TBV that were comparable to nondiseased animals, and significantly higher than the TBV in the other two groups of diseased animals (Po0.05). Similar effects were seen on trabecular number (Figure 5e ) and thickness (Figure 5g ) in the vertebrae.
Similar effects on bone loss were seen in the tibiae of diseased animals. While animals injected with MM cells alone, or in combination with control MSC demonstrated significant loss of TBV (Figure 5d ), animals that received MM cells with MSC OPG had TBV levels that were comparable to those of non-diseased controls. Similar effects were seen for trabecular number (Figure 5f ) and thickness (Figure 5h ), although the latter remained below the levels in non-diseased controls.
Thus in vivo administration of hMSC expressing OPG by lentiviral gene transfer is able to reverse osteoclast activation and reduce bone loss in this KMS-12-BM xenogeneic model. A new xenograft model of myeloma bone disease N Rabin et al
Discussion
Here we have described an in vivo model of medullary myeloma with associated bone disease that is consistently demonstrable and quantifiable by micro-CT and histology. There is clear evidence of osteoclast activation and osteoblast suppression, which are directly related to the level of bone marrow infiltration. Importantly, the use of OPG expressing hMSC was able to reverse osteoclast activation and restore bone volume in diseased animals. Current in vivo models of myeloma have contributed greatly to our understanding of the cellular and molecular bases for bone loss, however, there is a lack of readily reproducible medullary models of human myeloma which can be used to test strategies aimed at bone disease and the bone marrow microenvironment. Immunodeficient models employing myeloma cell lines cultured in vitro frequently develop extramedullary disease, [16] [17] [18] [19] whereas the SCID-hu 20 and SCID-rab 21 models do not reflect the systemic nature of the disease. The myeloma cell line KMS-12-BM was established from a patient with nonsecretory MM and has not previously been described in an animal model. These cells engraft in unconditioned b 2 m NOD/ SCID mice with the development of local tumours when delivered subcutaneously. Importantly, tail vein administration leads to engraftment within the bone marrow, with little or no extramedullary involvement. The b 2 m NOD/SCID mouse strain, which lack mature lymphocytes, serum immunoglobulin and natural killer (NK) cell activity allows engraftment of xenogeneic cells 27 and KMS-12-BM cells engraft without need for conditioning. Engraftment occurs with reproducible kinetics over a 6-week period (at a cell dose of 10 7 /animal), thus allowing consistent timing of interventions.
An important feature of the KMS-12-BM xenogeneic model is the presence of osteolytic bone disease, manifested by loss of cortical and trabecular bone in tibiae and trabecular bone in the vertebrae. Importantly, bone loss varies directly with extent of disease infiltration, and is associated both with an increase in osteoclasts, and a reduction in osteoblasts. The confinement of disease to medullary sites, even until the terminal phases, indicates that this tumour model is dependent upon the bone A new xenograft model of myeloma bone disease N Rabin et al marrow microenvironment and would be useful and appropriate to test strategies directed at this environment. This model also closely resembles the clinical disease, where extensive bone destruction is commonly associated with medullary forms of myeloma, in contrast to extramedullary myeloma where lytic bone disease is less frequent. Furthermore, bone loss is quantifiable, both by histomorphometry and by micro-CT. Use of micro-CT in this model will allow us to study the processes and mechanisms of bone loss at different stages of the disease. Interestingly, bone loss in the lumbar vertebrae was detected by micro-CT but not by histomorphometry, suggesting that micro-CT maybe a more sensitive tool. Certainly, this model affords a detailed and comprehensive analysis of both cortical and trabecular bone and will be a valuable tool to study the processes and mechanisms of bone loss in MM.
Blockade of RANKL with OPG or recombinant RANK has been demonstrated in animal models of myeloma to reduce the associated bone disease and, in some reports, to increase survival. 7, 14, 28, 29 In patients with myeloma and breast cancerrelated bone metastases, bone resorption was reduced by recombinant OPG treatment, an effect that was comparable to a single injection of a bisphosphonate. 30 Recombinant OPG when administered systemically has a half-life of several days, thus to obtain a clinically significant response would require multiple injections over a period of time. In a xenogeneic model of osteolytic bone disease, Doran et al. 31 directly transduced the ARH-77 cell line to express hOPG and demonstrated a reduction in bone disease. Although providing proof of principle, this strategy is not suitable for clinical application. Genetically modified MSC provide a novel way of delivering OPG, with the potential for sustained expression. Our results confirm the efficacy of this approach. In addition, the reduction in osteoclast numbers, and attenuation of bone loss achieved by the use of MSC OPG provide direct evidence that the OPG/ RANKL axis is important in this model of MM bone disease.
We timed our intervention to coincide with engraftment of KMS-12-BM in the bone marrow, with weekly tail vein injections of gene-modified MSC from 2 weeks onward. While our results are encouraging and provide proof of principle, there is scope for further optimization of the treatment schedule. Trabecular bone may have been lost (for example, from the tibiae) before the intervention was started, and earlier timing of treatment may enhance the therapeutic effect. Additionally levels of OPG may not be high enough to completely block osteoclast activation. In an in vitro co-culture system, 6 hOPG inhibited osteoclast differentiation by 50% at a concentration of 1 ng/ml (similar to levels we have detected in vivo following injection of MSC OPG ), however, complete suppression of osteoclast differentiation required levels of 10-100 ng/ml, which may not have been achieved by the schedule of treatment used here. Furthermore the presence of syndecan-1 expressed on myeloma cells (including KMS-12-BM) may bind and inactivate OPG, thus limiting its bioavailability 32 in this model. Finally enforced expression of OPG, while inhibiting osteoclast activation, does not alter osteoblast suppression, which may be required to produce a complete reversal of bone loss in our model.
MSCs are a subset of non-haemopoietic progenitor cells that are capable of differentiating into mesenchymal tissues including osteoblasts, adipocytes, chondrocytes and myocytes. 33 Data A new xenograft model of myeloma bone disease N Rabin et al from animal experiments and a clinical trial suggest that the conditions characterized by increased cell turnover and tissue remodelling provide effective signals necessary for the survival and proliferation of systemically delivered MSC. 34, 35 While MSCs have been shown to poorly engraft in healthy tissues, 36 they have been shown to preferentially integrate in sites of tumours in animal models. 37, 38 Systemically delivered MSC, expressing therapeutic transgene led to tumour regression. 38, 39 In keeping with these reports, we observed that the presence of tumour cells in the bone marrow enhanced the short-term localization of infused MSC. Thus bone marrow-derived MSCs are attractive candidates to deliver therapeutic transgenes to the tumour environment in vivo, although clearly further work is needed to optimize their efficacy. We have recently demonstrated that overexpression of CXCR4 improves short-term homing of MSC to the bone marrow of irradiated b 2 m NOD/ SCID mice (Kyriakou et al., Blood 2006; 108: abstract 3182). Another potential advantage of MSC is their ability to differentiate into osteoblast progenitors. In support of this hypothesis is a recent report that MSC, when injected into tumour bearing bones, differentiated into osteoblasts, and reduced bone destruction in the SCID-Hu model. 40 In myeloma, unopposed osteoclast activation resulting in bone destruction, fractures and deformity presents one of the most challenging aspects of this disease for both patients and their physicians. We describe a new xenogeneic model of myeloma bone disease, in which increased osteoclasts and reduced osteoblasts results in bone destruction which is quantifiable by histomorphometry and micro-CT. In addition, we have employed a novel strategy to deliver OPG in vivo and demonstrated that this approach is able to reverse osteoclast activation and restore bone volume. A full reversal of MM induced bone disease may require the coordinate use of strategies to augment osteoblast function 13 as well as inhibiting osteoclast activation.
